+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

SU-E-T-297: Proton-Therapy System for Treatment of Macular Degeneration and Ocular Malignancies



SU-E-T-297: Proton-Therapy System for Treatment of Macular Degeneration and Ocular Malignancies



Medical Physics 39(6part14): 3771-3772



To commission a proton-therapy system for the treatment of uveal melanoma and age-related macular degeneration. Proton therapy system is the proto-type of a commercial product developed by Ion Beam Applications. Proton beam is brought into the treatment room at 105 MeV through a fixed beam line. A single-scattering system with absorber/scattering foils spreads the beam into a Gaussian profile. A library of 10 range-modulator wheels and 16 range-modulator blocks generate spread-out Bragg peaks of various range and modulation width. Source-to-axis distance of the system is 169 cm. Two orthogonal digital x-ray panels are used for alignment. EyePlan software is used both for both treatment planning and in-room alignment. Range can be varied continuously between 0.5 and 3.4 g/cm2 . Range accuracy is measured to be better than 0.05 g/cm2 . Modulation width can be varied in steps of =0.3 g/cm2 with an accuracy of 0.05 g/cm2 or 2%. Maximum aperture diameter is 2.5 cm and maximum dose rate >32 Gy/min. Strong dependence of output on range (7%/mm) and dose rate (0.2%/(Gy/min)) is found. Distal and lateral fall-off (80%-20%) are =0.23 and =0.18 g/cm2 and do not depend much on range or depth. When reducing the aperture diameter to 6 mm no significant change is observed in shape of depth-dose curve or absolute dose (<2.5%). Measurements show a significant portion of the dose at shallow depth (=0.7 g/cm2 ) is delivered by protons scattering off of snout elements. Simple collimation could reduce this effect. The dosimetric and positioning properties of the IBA ocular proton system are adequate to treat ocular lesions with acceptable clinical margins. Suggested improvements include limiting the output-dependence on range and reducing snout scatter.

(PDF emailed within 1 workday: $29.90)

Accession: 060293525

Download citation: RISBibTeXText

PMID: 28517276


Related references

Technical Note: Dosimetric characteristics of the ocular beam line and commissioning data for an ocular proton therapy planning system at the Proton Therapy Center Houston. Medical Physics 44(12): 6661-6671, 2017

Update on ocular gene therapy and advances in treatment of inherited retinal diseases and exudative macular degeneration. Current Opinion in Ophthalmology 27(3): 268-273, 2016

Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Archives of Ophthalmology 117(10): 1329-1345, 1999

Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study Report no. 4. Retina 24(1): 1-12, 2004

Radiotherapy and the treatment of age-related macular degeneration. External beam radiation therapy is effective in the treatment of age-related macular degeneration. Archives of Ophthalmology 116(11): 1507-1511, 1998

Verteporfin Ocular Photodynamic Therapy Combined with Macular Scatter Photocoagulation for Occult or Predominantly Occult Subfoveal Neovascularization in Age-Related Macular Degeneration. ARVO Annual Meeting Abstract Search & Program Planner : Abstract No 575, 2002

Verteporfin ocular photodynamic therapy combined with macular scatter photocoagulation fo occult or predominantly occult subfoveal neovascularization in age related macular degeneration a follow up. ARVO Annual Meeting Abstract Search & Program Planner : Abstract No 4999, 2003

Proton therapy of occult neovessels in age-related macular degeneration. Journal Francais d'Ophtalmologie 24(9): 949-954, 2002

Treatment of macular degeneration with proton beams. Medical Physics 26(5): 777-782, 1999

Proton beam radiation therapy in the treatment of pediatric central nervous system malignancies: a review of the literature. Journal of Pediatric Oncology Nursing 26(3): 142-149, 2009

Proton beam therapy for age-related macular degeneration: development of a standard plan. Medical Dosimetry 24(4): 233-238, 2000

Virtual commissioning of a treatment planning system for proton therapy of ocular cancers. Radiation Protection Dosimetry 115(1-4): 159-163, 2005

The role of complement system in ocular diseases including uveitis and macular degeneration. Molecular Immunology 44(16): 3901-3908, 2007

A model of the ocular pharmacokinetics involved in the therapy of neovascular age-related macular degeneration with ranibizumab. British Journal of Ophthalmology 99(11): 1554-1559, 2016

Proton therapy for exudative age-related macular degeneration: A randomized, sham-controlled clinical trial. American Journal of Ophthalmology 134(6): 905-906, 2002